Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1990-02-22
1991-07-09
Kepplinger, Esther L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 8, 530350, 530395, 530806, 530808, 530828, 424 88, 424 89, 424 93, 435 711, 4352402, 4352403, C07K 1514, A61K 3702
Patent
active
050306219
ABSTRACT:
A human anti-cancer vaccine is prepared by culturing human cancer cells, such as human melanoma cells, human lung cancer cells, human colon cancer cells, human breast cancer cells, and other human cancer cells in a serum-free medium. The cells are selected on the basis of expressing different patterns of cell surface tumor antigens and are adapted to and are grown in a serum-free medium. During culturing antigens of the cancer cells are shed into the culture medium. The culture medium, containing the shed cancer cell antigens, is then concentrated, such as by vacuum ultrafiltration. In some instances the vaccine is then treated with a non-ionic surfactant or detergent, such as Nonidet P-40 (NP-40), to break up aggregates and treated with a presevative, such as sodium azide, and then subjected to ultracentrifugation. The supernatant is then dialyzed against normal saline with a small amount of sodium azide and made up to the desired protein concentration by the addition of normal saline and subjected to filtration to remove any microorganisms. When used as an anti-cancer vaccine, the resulting composition is administered to the patients, such as intradermally. In the instance where the patients are cancer patients, the vaccine is administered to the patient intradermally over a period of weeks, with or without an adjuvant, into each of the four extremities at the desired dose, e.g. from an initial dosage of about 0.25 ug/site up to about 50 ug/site. By following the practices of this invention there has been prepared a polyvalent human melanoma antigen vaccine containing multiple melanoma associated antigens (MAAs) and free of detectable fetal calf serum (FCS) proteins and Dr antigens.
REFERENCES:
patent: 3960827 (1976-06-01), Bjorklund
patent: 4108903 (1978-08-01), Wallack
patent: 4150150 (1979-04-01), Straub
patent: 4160018 (1979-07-01), Bjorklund
patent: 4160019 (1979-07-01), Bjorklund
patent: 4211766 (1980-07-01), Bjorklund
patent: 4323555 (1982-04-01), Thielen
patent: 4383985 (1983-05-01), Bartorelli et al.
patent: 4415553 (1983-11-01), Zhabilov et al.
patent: 4434157 (1984-02-01), Olsen
patent: 4562160 (1985-12-01), Real et al.
patent: 4591572 (1986-05-01), Mattes et al.
patent: 4720386 (1988-01-01), McCollester
Bystryn et al., Clin. Res., 34(2), 561A, (May 1986).
Bystryn et al., Cancer Research, 45, 5603-5607, (1985).
Johnston et al., Cancer Research, 45, 1772-1777 (1985).
Heaney-Kieras et al., JNCI, 77(3) 643-647, (1986).
Bystryn et al., Cancer Research, 41, 910-914 (1981).
Boctor et al., Cancer Research, 42, 2121-2125 (1982).
Heaney-Kieras et al., Cancer Research, 42, 2310-2316 (1982).
Bystryn et al., Cancer Research, 42, 2232-2237 (1982).
Sutherland et al., Biol. Abs. 76 (1), 4378, p. 469, 1983 (for J. Surg. Oncol., 20(4), 221-226, 1982).
CA 73:85933m, Zatula, 1970.
CA 73:85940m, Rand Dev. Corp., 1970.
CA 89:4357g, Ng et al., 1978.
CA 84:173965f, Gautam et al., 1976.
Chirigos et al., Cancer Res. 38, 1085-1091, 1978.
Seigler et al., Ann. Surg., 190(3), 366-372, Sept. 1979.
Kataoka et al., Cancer Res., 40, 3839-3845, Oct. 1980.
Livingston et al., Cancer, 55, 713-720, Feb. 1985.
CA 91:37350u, Ray et al., 1979.
Wright et al., Cancer Res., 37, 4228-4232, Nov. 1977.
Reisfield et al., Cancer Res., 37, 2860-2865, Aug. 1977.
Kessler et al., Cancer Res., 38, 1041-1048, Apr. 1978.
Leung et al., J. Immunol., 119(2), (1977), pp. 664-670.
Chem. Ab. 93: 43610m, Kamiyama et al., 1980.
CA 93:43566b, Kataoka, 1980.
CA 93:19533t, McCollester, 1980.
Bystryn et al., J. Biol. Resp. Mod., 5(3), 211-224 (Jun. 1986).
Johnson et al., Fed. Proc., 44(3), p. 797, Abs. 2257 (1985).
Johnston et al., Biol. Abs. 84(1); 6296 (pub. date Jan. 1987).
Bystryn, J. Immunol., 120(1), 96-101 (1978).
Livingston et al., Cancer, 56(9), 2194-2200 (1985).
Kepplinger Esther L.
Kushan Jeff
LandOfFree
Shed melanoma antigen compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Shed melanoma antigen compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Shed melanoma antigen compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-618290